Skip to main content
. Author manuscript; available in PMC: 2024 Apr 25.
Published in final edited form as: JACC Heart Fail. 2023 Feb;11(2):211–223. doi: 10.1016/j.jchf.2022.11.007

Figure 3. Post-discharge Outcomes of Heart Failure Patients Eligible for Vericiguat.

Figure 3.

Shows the cumulative incidence plots of all-cause mortality, all cause readmission and heart failure admission for the 3 cohorts: hospitalized HF with EF<45% population, FDA label and VICTORIA eligible patients. The 3 cohorts are represented by red, blue and green colors respectively.